

# QIPS 2025: Adult program

## Statin Therapy for Patients with Cardiovascular Disease

Stars Measure | Tertiary Focus | Statin Therapy



### Measure Requirements

Eligible Commercial and Medicare Advantage male members ages 21 through 75 and female members ages 40 through 75 as of December 31, 2025, identified as having ASCVD.

### Member Requirements

Evaluates the percentage of males ages 21 through 75 and females ages 40 through 75 during the measurement year (2025) who are identified as having clinical atherosclerotic cardiovascular disease (ASCVD) and met the following criteria:

- **Statin adherence 80%.** Members who remained on a high-intensity or moderate-intensity statin medication for at least 80% of the treatment period.
- **Received statin therapy.** Members who were dispensed at least one moderate-intensity or high-intensity statin medication during 2025.

Also, members did not have the following in the measurement year or the year prior to the measurement year:

- Diagnosis of pregnancy
- In vitro fertilization
- Dispensed at least one prescription for clomiphene (Clomid®)
- ESRD
- Cirrhosis
- Myalgia
- Myositis
- Rhabdomyolysis

### QPM Targets

Band 1	94% – 100%
Band 2	90% – 93.99%
Band 3	87% – 89.99%
Band 4	84% – 86.99%
Band 5	<84%

See payment details in section 5 of the QIPS guide.

Independence Blue Cross offers products through its subsidiaries Independence Assurance Company, Independence Hospital Indemnity Plan, Keystone Health Plan East, and QCC Insurance Company — independent licensees of the Blue Cross and Blue Shield Association.



## Options to close Care Gaps

- **Option 1:** Claim/encounter submission with appropriate coding of pharmaceuticals from a pharmacy.

Description	Prescription		
<b>Moderate-intensity statin therapy</b>	Atorvastatin 10 – 20 mg	Amlodipine-atorvastatin 10 – 20 mg	Rosuvastatin 5 – 10 mg
	Simvastatin 20 – 40 mg	Ezetimibe-simvastatin 20 – 40 mg	Pravastatin 40 – 80 mg
	Lovastatin 40 mg	Fluvastatin 40 mg bid	Pitavastatin 2 – 4 mg
<b>High-intensity statin therapy</b>	Atorvastatin 40 – 80 mg	Amlodipine-atorvastatin 40 – 80 mg	Rosuvastatin 20 – 40 mg
	Simvastatin 80 mg	Ezetimibe-simvastatin 80 mg	

- **Option 2:** Claim/encounter submission with appropriate exclusion coding for members who meet any of the following criteria on or prior to December 31 of the measurement year (2025). Please refer to the *Gap Closures Guide – Adults* for the list of appropriate exclusion codes.